Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
MDS-PB13 Score - Blood based detection of aberrancies by flow cytometry in patients with suspected and confirmed Myelodysplastic Neoplasms.
Leukemia. 2024 Feb;38(2):446-450. doi: 10.1038/s41375-024-02141-w. Epub 2024 Jan 16.
Leukemia. 2024.
PMID: 38228682
Free PMC article.
No abstract available.
Identification of critical hemodilution by artificial intelligence in bone marrow assessed for minimal residual disease analysis in acute myeloid leukemia: The Cinderella method.
Hoffmann J, Thrun MC, Röhnert MA, von Bonin M, Oelschlägel U, Neubauer A, Ultsch A, Brendel C.
Hoffmann J, et al. Among authors: rohnert ma.
Cytometry A. 2023 Apr;103(4):304-312. doi: 10.1002/cyto.a.24686. Epub 2022 Sep 12.
Cytometry A. 2023.
PMID: 36030398
Free article.
Item in Clipboard
Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia.
Röhnert MA, Kramer M, Schadt J, Ensel P, Thiede C, Krause SW, Bücklein V, Hoffmann J, Jaramillo S, Schlenk RF, Röllig C, Bornhäuser M, McCarthy N, Freeman S, Oelschlägel U, von Bonin M.
Röhnert MA, et al.
Leukemia. 2022 Sep;36(9):2208-2217. doi: 10.1038/s41375-022-01647-5. Epub 2022 Jul 18.
Leukemia. 2022.
PMID: 35851154
Free PMC article.
Item in Clipboard
The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemia.
Vucinic V, Ruhnke L, Sockel K, Röhnert MA, Backhaus D, Brauer D, Franke GN, Niederwieser D, Bornhäuser M, Röllig C, Platzbecker U, Schwind S, Jentzsch M.
Vucinic V, et al. Among authors: rohnert ma.
Blood Adv. 2021 Dec 28;5(24):5584-5587. doi: 10.1182/bloodadvances.2021005974.
Blood Adv. 2021.
PMID: 34670273
Free PMC article.
No abstract available.
Item in Clipboard
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia.
Rautenberg C, Stölzel F, Röllig C, Stelljes M, Gaidzik V, Lauseker M, Kriege O, Verbeek M, Unglaub JM, Thol F, Krause SW, Hänel M, Neuerburg C, Vucinic V, Jehn CF, Severmann J, Wass M, Fransecky L, Chemnitz J, Holtick U, Schäfer-Eckart K, Schröder J, Kraus S, Krüger W, Kaiser U, Scholl S, Koch K, Henning L, Kobbe G, Haas R, Alakel N, Röhnert MA, Sockel K, Hanoun M, Platzbecker U, Holderried TAW, Morgner A, Heuser M, Sauer T, Götze KS, Wagner-Drouet E, Döhner K, Döhner H, Schliemann C, Schetelig J, Bornhäuser M, Germing U, Schroeder T, Middeke JM.
Rautenberg C, et al. Among authors: rohnert ma.
Blood Cancer J. 2021 Oct 4;11(10):164. doi: 10.1038/s41408-021-00558-5.
Blood Cancer J. 2021.
PMID: 34608129
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite